Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (375)	2/3/2016 8:29:06 PM
From: tuck	Read Replies (1) \| Respond to of 684

I recall BIND missing a shot on goal not too long ago. You think there's anything worth searching the wreckage for there? Cheers, Tuck

To: rkrw who wrote (375)	2/4/2016 1:17:58 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 684

Wonderful resource, thank you! >> Cmrx << Presenting at BMT Tandem 2016 on the 20th. Looking at subset of SUPPRESS who were NOT treated for GvH...... the T cell depleted subset. At JPM, company indicated that this subset mimics phase II results. (please check the presentation yourself for exact wording.... thanks!) Again, 9/30 cash was $8.20/share. Book was $391m, or approximately 8.48/share. Burn for qtr was $31m. Current share price $7.32.